Q2 2023 13F Holders as of 6/30/2023
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
61.8M
-
Number of holders
-
68
-
Total 13F shares, excl. options
-
39.7M
-
Shares change
-
-34.3K
-
Total reported value, excl. options
-
$272M
-
Value change
-
-$3.2M
-
Number of buys
-
41
-
Number of sells
-
-20
-
Price
-
$6.85
Significant Holders of Monte Rosa Therapeutics, Inc. - Common Stock, par value $0.0001 per share (GLUE) as of Q2 2023
79 filings reported holding GLUE - Monte Rosa Therapeutics, Inc. - Common Stock, par value $0.0001 per share as of Q2 2023.
Monte Rosa Therapeutics, Inc. - Common Stock, par value $0.0001 per share (GLUE) has 68 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 39.7M shares
of 61.8M outstanding shares and own 64.31% of the company stock.
Largest 10 shareholders include NEA Management Company, LLC (7.69M shares), FMR LLC (6.55M shares), Avoro Capital Advisors LLC (4.54M shares), PRICE T ROWE ASSOCIATES INC /MD/ (3.9M shares), BlackRock Inc. (3.86M shares), BAKER BROS. ADVISORS LP (3.02M shares), VANGUARD GROUP INC (1.56M shares), Aisling Capital Management LP (1.47M shares), Alphabet Inc. (1.46M shares), and CITADEL ADVISORS LLC (772K shares).
This table shows the top 68 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.